TFFP Stock Overview
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia.
TFF Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.75|
|52 Week High||US$10.70|
|52 Week Low||US$3.60|
|1 Month Change||-0.35%|
|3 Month Change||-20.36%|
|1 Year Change||-39.47%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||13.41%|
Recent News & Updates
TFF Pharmaceuticals: A Highly Attractive Basket Of Options
TFFP is a platform company with leading technology. Clinical/FDA risk is extremely low. The stock is drastically undervalued based on only fraction of the pipeline and multiples of upside. Multiple insider purchases support the bull case and timing.
We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|TFFP||US Pharmaceuticals||US Market|
Return vs Industry: TFFP underperformed the US Pharmaceuticals industry which returned 10.3% over the past year.
Return vs Market: TFFP underperformed the US Market which returned -19.1% over the past year.
|TFFP Average Weekly Movement||9.0%|
|Pharmaceuticals Industry Average Movement||12.0%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: TFFP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: TFFP's weekly volatility (9%) has been stable over the past year.
About the Company
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company’s lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.
TFF Pharmaceuticals Fundamentals Summary
|TFFP fundamental statistics|
Is TFFP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TFFP income statement (TTM)|
|Cost of Revenue||US$21.28m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.25|
|Net Profit Margin||-24,192.49%|
How did TFFP perform over the long term?See historical performance and comparison
Is TFFP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TFFP?
Other financial metrics that can be useful for relative valuation.
|What is TFFP's n/a Ratio?|
Price to Book Ratio vs Peers
How does TFFP's PB Ratio compare to its peers?
|TFFP PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
MRNS Marinus Pharmaceuticals
MIST Milestone Pharmaceuticals
VRNA Verona Pharma
PRVB Provention Bio
TFFP TFF Pharmaceuticals
Price-To-Book vs Peers: TFFP is expensive based on its Price-To-Book Ratio (4.6x) compared to the peer average (2.9x).
Price to Earnings Ratio vs Industry
How does TFFP's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: TFFP is expensive based on its Price-To-Book Ratio (4.6x) compared to the US Pharmaceuticals industry average (1.8x)
Price to Book Ratio vs Fair Ratio
What is TFFP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||4.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate TFFP's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of TFFP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TFFP ($5.75) is trading below our estimate of fair value ($471.91)
Significantly Below Fair Value: TFFP is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TFFP's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is TFF Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TFFP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: TFFP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TFFP is expected to become profitable in the next 3 years.
Revenue vs Market: TFFP's revenue (71.2% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: TFFP's revenue (71.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TFFP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has TFF Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TFFP is currently unprofitable.
Growing Profit Margin: TFFP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TFFP is unprofitable, and losses have increased over the past 5 years at a rate of 44.1% per year.
Accelerating Growth: Unable to compare TFFP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TFFP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.5%).
Return on Equity
High ROE: TFFP has a negative Return on Equity (-100.55%), as it is currently unprofitable.
Discover strong past performing companies
How is TFF Pharmaceuticals's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: TFFP's short term assets ($31.5M) exceed its short term liabilities ($2.2M).
Long Term Liabilities: TFFP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: TFFP is debt free.
Reducing Debt: TFFP has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TFFP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TFFP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is TFF Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TFFP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TFFP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TFFP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TFFP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TFFP has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Glenn Mattes (67 yo)
Mr. Glenn R. Mattes serves as Director at Viking Scientific, Inc. He serves as Chief Executive Officer, President and Director of TFF Pharmaceuticals, Inc. since May 1, 2018. Mr. Mattes has oversight of th...
CEO Compensation Analysis
Compensation vs Market: Glenn's total compensation ($USD596.25K) is about average for companies of similar size in the US market ($USD800.58K).
Compensation vs Earnings: Glenn's compensation has been consistent with company performance over the past year.
Experienced Management: TFFP's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: TFFP's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TFFP insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
TFF Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: TFF Pharmaceuticals, Inc.
- Ticker: TFFP
- Exchange: NasdaqGM
- Founded: 2018
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$145.899m
- Shares outstanding: 25.37m
- Website: https://www.tffpharma.com
Number of Employees
- TFF Pharmaceuticals, Inc.
- 1751 River Run
- Suite 400
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/05 00:00|
|End of Day Share Price||2022/07/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.